Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Common Equity (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Common Equity for 16 consecutive years, with $143.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 6.83% to $143.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $143.5 million through Dec 2025, down 6.83% year-over-year, with the annual reading at $143.5 million for FY2025, 6.83% down from the prior year.
  • Common Equity for Q4 2025 was $143.5 million at Anika Therapeutics, down from $146.8 million in the prior quarter.
  • The five-year high for Common Equity was $290.1 million in Q3 2021, with the low at $143.5 million in Q4 2025.
  • Average Common Equity over 5 years is $232.8 million, with a median of $272.3 million recorded in 2023.
  • The sharpest move saw Common Equity increased 5.39% in 2021, then tumbled 33.5% in 2024.
  • Over 5 years, Common Equity stood at $287.1 million in 2021, then dropped by 0.53% to $285.6 million in 2022, then fell by 25.67% to $212.3 million in 2023, then fell by 27.45% to $154.0 million in 2024, then fell by 6.83% to $143.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $143.5 million, $146.8 million, and $147.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.